Toll-like receptor agonists: are they good adjuvants?
Toll-like receptor agonists: are they good adjuvants?
复制标题
DOI：
10.1097/ppo.0b013e3181eaca65
复制
发表时间：
2010-07
期刊：
影响因子：
--
通讯作者：
Bhardwaj N
中科院分区：
文献类型：
--
作者：
Gnjatic S;Sawhney NB;Bhardwaj N
导致癌症消退的治疗性免疫仍然是一个重大挑战。成功的免疫需要激活适应性免疫，包括肿瘤特异性CD4+T细胞和CD8+T细胞。一般来说，癌症患者的 T 细胞活化因免疫抑制、肿瘤抗原表达丧失和抗原呈递细胞 (APC) 功能障碍而受到损害。树突状细胞 (DC) 等 APC 是诱导适应性抗肿瘤免疫反应的关键。最近，人们的注意力集中在增强 DC 功能及其启动 T 细胞的能力的新型佐剂上。针对 Toll 样受体 (TLR) 的激动剂在临床上单独使用或与肿瘤抗原联合使用，并在增强免疫反应和引发抗肿瘤活性方面取得了初步成功。这篇综述总结了这些佐剂在治疗癌症方面的应用以及增强体内反应的潜力。
Therapeutic immunization leading to cancer regression remains a significant challenge. Successful immunization requires activation of adaptive immunity, including tumor specific CD4 + T cells and CD8+ T cells. Generally speaking, the activation of T cells is compromised in patients with cancer due to immune suppression, loss of tumor antigen expression, and dysfunction of antigen presenting cells (APC). APC such as dendritic cells (DC) are key for the induction of adaptive anti-tumor immune responses. Recently, attention has focused on novel adjuvants that enhance DC function and their ability to prime T cells. Agonists that target toll-like receptors (TLR) are being used clinically either alone or in combination with tumor antigens and showing initial success both in terms of enhancing immune responses and eliciting anti-tumor activity. This review summarizes the application of these adjuvants to treat cancer and the potential for boosting responses in vivo.